Page last updated: 2024-11-10

torulene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

torulene : A carotene that is beta,psi-carotene which has been been dehydrogenated to introduce an (E)-double bond at the 3'-4' position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281253
CHEBI ID9638
MeSH IDM0211424

Synonyms (20)

Synonym
LMPR01070088
547-23-9
torulene
C08613 ,
3',4'-didehydro-beta,psi-carotene
2-[(1e,3e,5e,7e,9e,11e,13e,15e,17e,19e,21e)-3,7,12,16,20,24-hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,21,23-dodecaenyl]-1,3,3-trimethylcyclohexene
unii-7kkr9cwx9p
beta,psi-carotene, 3',4'-didehydro-
torulin
7kkr9cwx9p ,
CHEBI:9638
(3'e)-3',4'-didehydro-beta,psi-carotene
Q7827444
DTXSID901029634
(3'z)-3',4'-didehydro-beta,psi-carotene
3,4-didehydro-.beta.,.psi.-carotene
all-trans-torulene
.beta.,.psi.-carotene, 3,4-didehydro-
.gamma.-carotene, 3,4-didehydro-, all-trans-
2-((1e,3e,5e,7e,9e,11e,13e,15e,17e,19e,21e)-3,7,12,16,20,24-hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,21,23-dodecaenyl)-1,3,3-trimethylcyclohexene

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The gene dosage of in vitro evolved lycopene cyclase crtY2 significantly changed the carotenoid profile."( Investigation of factors influencing production of the monocyclic carotenoid torulene in metabolically engineered Escherichia coli.
Lee, PC; Mijts, BN; Schmidt-Dannert, C, 2004
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
caroteneHydrocarbon carotenoids.
polyeneAn olefin that contains more than one carbon-carbon double bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
neurosporaxanthin biosynthesis314

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (5.26)18.7374
1990's0 (0.00)18.2507
2000's18 (47.37)29.6817
2010's14 (36.84)24.3611
2020's4 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.77 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index5.34 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]